Clinical Trial

The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of chidamide, anti-PD1 antibody, and pegaspargase versus dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP) in the treatment of newly diagnosed, stage III to IV extranodal natural killer/T-cell lymphoma.
Trial Details
NCT Number NCT06255795
Lead Sponsor Ruijin Hospital
Conditions Extranodal Natural Killer T Cell Lymphoma
Enrollment 142 participants
Start Date 2024-02-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-13